ReviewExpert opinion on biological therapy2012
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Review in Expert opinion on biological therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 191 citations in OpenAlex.
- Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.Frontiers of medicine · 2018Pooled it
- Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants.Drug design, development and therapy · 2023Trial
- Type 2 inflammation, bronchiectasis and clinical trials: expanding from MAHALE.ERJ open research · 2026Article
- Successful clinical remission of severe asthma with small airway dysfunction and eosinophilic gastrointestinal disease using dupilumab after benralizumab failure.Respiratory medicine case reports · 2026Article
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis.Biomedicines · 2025Review
- Dual pathogenesis and treatment approaches for eosinophilic granulomatosis with polyangiitis: a comprehensive review.Reumatologia · 2025Review
- Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma.Journal of clinical medicine · 2024Article
- Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events.Journal for immunotherapy of cancer · 2024Article
- Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles.Life (Basel, Switzerland) · 2024Review
- The Evolution of Scientific Knowledge in Childhood Asthma over Time: A Surprising History.Children (Basel, Switzerland) · 2024Review
- Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report.BMC geriatrics · 2024Article
- Novel and potential future therapeutic options in systemic autoimmune diseases.Frontiers in immunology · 2024Review
- Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.Clinical reviews in allergy & immunology · 2023Review
- Asthma Phenotypes in the Era of Personalized Medicine.Journal of clinical medicine · 2023Review
- The evolving landscape of immunotherapy for the treatment of allergic conditions.Clinical and translational science · 2023Review
- The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach.Respiratory research · 2023Article
- Biologics and airway remodeling in severe asthma.Allergy · 2022Review
- Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma.Respiratory research · 2022Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionBenralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. AREAS COVERED: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. EXPERT OPINION: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.